M. Troya-Martín, F. Rivas-Ruíz, N. Blázquez-Sánchez, I. Fernández-Canedo, M. Aguilar-Bernier, J. B. Repiso-Jiménez, J. C. Toribio-Montero, M. Jones‐Caballero, J. Rhee
{"title":"Responsiveness of the Spanish Version of the “Skin Cancer Index”","authors":"M. Troya-Martín, F. Rivas-Ruíz, N. Blázquez-Sánchez, I. Fernández-Canedo, M. Aguilar-Bernier, J. B. Repiso-Jiménez, J. C. Toribio-Montero, M. Jones‐Caballero, J. Rhee","doi":"10.1155/2016/8180348","DOIUrl":null,"url":null,"abstract":"Background. Skin Cancer Index (SCI) is a specific questionnaire measuring health related quality of life (HRQL) in patients with cervicofacial non-melanoma skin cancer (CFNMSC). The original scale has recently been adapted and validated into Spanish. Objectives. Evaluate the responsiveness of the Spanish version of SCI. Methods. Patients with CFNMSC candidate for surgical treatment were administered the questionnaire at time of diagnostic (t 0), 7 days after surgery (t 1), and 5 months after surgery (t 2). The scale and subscales scores (C1: social/appearance, C2: emotional) were then evaluated. Differences between t 0-t 1, t 1-t 2, and t 0-t 2 were determined and a gender-and-age segmented analysis was performed. Results. 88 patients, 54.8% male, mean age 62.5 years, completed the study. Differences between t 0-t 1 and t 1-t 2 scores were statistically significant (p < 0.05). The lowest values were found at time of diagnosis and postsurgery. Women and patients under 65 years showed the lowest values at the three times. Limitations. Concrete geographic and cultural area. Clinical and histological variables are not analysed. Conclusions. Our results confirm responsiveness of the Spanish version of the SCI. Further development of the instrument in Spanish-speaking countries and populations will make it possible to extend worldwide research and knowledge horizons on skin cancer.","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2016-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Skin Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2016/8180348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 5
Abstract
Background. Skin Cancer Index (SCI) is a specific questionnaire measuring health related quality of life (HRQL) in patients with cervicofacial non-melanoma skin cancer (CFNMSC). The original scale has recently been adapted and validated into Spanish. Objectives. Evaluate the responsiveness of the Spanish version of SCI. Methods. Patients with CFNMSC candidate for surgical treatment were administered the questionnaire at time of diagnostic (t 0), 7 days after surgery (t 1), and 5 months after surgery (t 2). The scale and subscales scores (C1: social/appearance, C2: emotional) were then evaluated. Differences between t 0-t 1, t 1-t 2, and t 0-t 2 were determined and a gender-and-age segmented analysis was performed. Results. 88 patients, 54.8% male, mean age 62.5 years, completed the study. Differences between t 0-t 1 and t 1-t 2 scores were statistically significant (p < 0.05). The lowest values were found at time of diagnosis and postsurgery. Women and patients under 65 years showed the lowest values at the three times. Limitations. Concrete geographic and cultural area. Clinical and histological variables are not analysed. Conclusions. Our results confirm responsiveness of the Spanish version of the SCI. Further development of the instrument in Spanish-speaking countries and populations will make it possible to extend worldwide research and knowledge horizons on skin cancer.
期刊介绍:
Journal of Skin Cancer is a peer-reviewed, Open Access journal that publishes clinical and translational research on the detection, diagnosis, prevention, and treatment of skin malignancies. The journal encourages the submission of original research articles, review articles, and clinical studies related to pathology, prognostic indicators and biomarkers, novel therapies, as well as drug sensitivity and resistance.